SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Wise who wrote ()4/30/1998 9:33:00 PM
From: muddphudd  Read Replies (1) of 2135
 
I saw this post on Yahoo:ENMD.

..."Also, I forgot to mention that Dr. Folkman also presented data in his lecture at EB'98 that these angiogenesis inhibitors were effective against leukemias! This is quite shocking since leukemia has long been referred to as the "liquid cancer". His contention is that in Acute Lymphoblastic Leukemia (ALL), the bone marrow of such patients becomes infiltrated with more blood vessels. So, maybe, just maybe some of these cancers would benefit from such anti-angiogenic therapies as well."

Interesting...

There was also some talk about a deal between JNJ and ENMD that is supposedly coming out very soon. The person who posted the note could not back it up with any 'real' information. Insinuated some 'insider info'. Who know.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News